

LOS ANGELES | SAN FRANCISCO | NEW YORK | BOSTON | SEATTLE | MINNEAPOLIS | MILWAUKEE

March 13, 2014

Michael Pachter (213) 688-4474

Nick McKay (213) 688-4343

Nick Citrin (213) 688-4495

# Amazon.com (AMZN - NEUTRAL): Amazon Announces Prime Membership Increase of \$20 to \$99; Maintain NEUTRAL, \$330 PT

Price: \$370.78 12-Month Price Target: \$330

- On Thursday, Amazon announced a price increase for Prime membership to \$99 annually. The \$20 increase was at the low end of the \$20 40 increase Amazon suggested during its Q4:13 conference call. While the company did not specifically provide a reason for the increase when it discussed the notion with investors earlier this year, we believe that the price increase is intended to offset increased usage of Prime and higher fuel costs.
- The price increase takes effect for existing members on renewals after April 17, and will apply to all new members. We estimate that there are approximately 25 million Prime members; the price increase will add roughly \$500 million to annualized revenue and operating profit when fully implemented, as it would require no additional expense. However, we think that Amazon intends to redeploy the incremental revenue into an expanded service offering for Prime members, most likely in the form of additions to the content catalog for its Amazon Prime Instant Video offering (provided free of charge to all Prime members) or in the form of same-day or next-day shipping on some items. We think it is exceedingly unlikely that Amazon will increase price on Prime without offering something of value to its Prime members, and we do not expect the company to pass through any incremental profit over the near term to investors. We estimate that the average Prime member receives 20 packages per year, and we believe that the prior \$79 fee barely covered the incremental cost of expedited shipping. We estimate that Amazon spends in excess of \$1 billion per year on streaming content, or an estimated \$40 per Prime member, suggesting that even with the price increase, the company will not cover its direct costs in providing the service.
- We estimate that Prime has 25 million members, and expect it to grow by at least 5 million annually, even with a price increase. We had previously expected Prime membership growth to accelerate in the coming quarters on a year-over-year basis, and although the price increase may stifle a portion of that growth, we think that Amazon fully expects to continue the momentum it saw in 2013. Prime membership was so popular this past holiday season that the company limited new signups during peak periods to ensure that the surge in new membership did not impact current members' service.
- Since introducing Prime nine years ago at \$79, Amazon had not increased prices (until today) while increasing the number of items available for Prime free, two-day shipping from one million to over 20 million. We believe Amazon will see only limited attrition in Prime members from the price increase, as the value proposition of a Prime membership continues to grow as Amazon adds more digital content and Sunday shipping through its partnership with the U.S. Postal Service. In our view, Prime members perceive great value in the free shipping feature, and over time, we expect them to perceive incremental value as Amazon Prime Instant Video builds its content catalog.
- Maintaining our NEUTRAL rating and \$330 price target. Our PT reflects a P/E multiple of 50x our hypothetical FY:19 EPS of \$8.38, discounted back five years. Our rating is based on our assessment that Amazon is unlikely to provide investors with a strategy road map. While recent announcements have given us increased visibility into Amazon's revenue growth, we are not convinced that the company will share sufficient details about spending plans to allow us to accurately model profit growth, and it may take time before EPS grows sufficiently to justify its share price.
- Investment Thesis: Amazon is a dominant online retailer well on its way to becoming one of the world's largest retailers, in our view. We believe the company enjoys considerable advantages over its brick-and-mortar competitors, due to its low direct overhead. Amazon management is quite ambitious, expanding into expensive digital media through its Kindle hardware and Prime video streaming, depressing the company's earnings power. Similarly, the expansion of Amazon Web Services has thus far been quite costly, although we think that AWS is at a tipping point and will generate significant leverage going forward. In order to take a position in Amazon, we believe investors must make a leap of faith that its revenues will continue to grow and will generate high contribution margin; we have made the leap of faith on revenues, but the lack of visibility on contribution margin gives us pause, and we prefer to stay on the sidelines. Accordingly, we are maintaining our NEUTRAL rating.
- Risks to the attainment of our share price target include a lack of financial visibility, increasing competition, changes in
  consumer preferences, changes to the terms or economics of its agreements with its customers or suppliers, dependence on
  its shipping partners, macroeconomic factors, an evolving tax environment, and legal, regulatory, and security risks, among
  other factors.

Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see page 2 of this report for analyst certification and important disclosure information.



#### **Analyst Certification**

I, Michael Pachter, Nick McKay, Nick Citrin, certify that the views expressed in this report accurately reflect my personal opinion and that I have not and will not, directly or indirectly, receive compensation or other payments in connection with my specific recommendations or views contained in this report.

Disclosure information regarding historical ratings and price targets is available at http://www.wedbush.com/ResearchDisclosure/DisclosureQ413.pdf

#### **Investment Rating System:**

Outperform: Expect the total return of the stock to outperform relative to the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months.

Neutral: Expect the total return of the stock to perform in-line with the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months.

Underperform: Expect the total return of the stock to underperform relative to the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months.

The Investment Ratings are based on the expected performance of a stock (based on anticipated total return to price target) relative to the other stocks in the analyst's coverage universe (or the analyst's team coverage).\*

Rating Distribution (as of December 31, 2013)	Investment Banking Relationships (as of December 31, 2013)
Outperform:54%	Outperform:18%
Neutral: 43%	Neutral: 2%
Underperform: 3%	Underperform: 0%

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis.

The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities.

#### Wedbush Equity Research Disclosures as of March 13, 2014

Company	Disclosure
Amazon.com	1

# Research Disclosure Legend

- WS makes a market in the securities of the subject company.
- 2. WS managed a public offering of securities within the last 12 months.
- 3. WS co-managed a public offering of securities within the last 12 months.
- 4. WS has received compensation for investment banking services within the last 12 months.
- 5. WS provided investment banking services within the last 12 months.
- 6. WS is acting as financial advisor.
- 7. WS expects to receive compensation for investment banking services within the next 3 months.
- 8. WS provided non-investment banking securities-related services within the past 12 months.
- 9. WS has received compensation for products and services other than investment banking services within the past 12 months.
- 10. The research analyst, a member of the research analyst's household, any associate of the research analyst, or any individual directly involved in the preparation of this report has a long position in the common stocks.
- 11. WS or one of its affiliates beneficially own 1% or more of the common equity securities.
- 12. The analyst maintains Contingent Value Rights that enables him/her to receive payments of cash upon the company's meeting certain clinical and regulatory milestones.

#### Price Charts

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request.





\* WS changed its rating system from (Strong Buy/Buy/Hold/Sell) to (Outperform/ Neutral/Underperform) on July 14, 2009. Please access the attached hyperlink for WS' Coverage Universe: <a href="http://www.wedbush.com/services/cmg/equities-division/research/equity-research">http://www.wedbush.com/services/cmg/equities-division/research/equity-research</a> Applicable disclosure information is also available upon request by contacting Ellen Kang in the Research Department at (213) 688-4529, by email to <a href="mailto:ellen.kang@wedbush.com">ellen.kang@wedbush.com</a>, or the Business Conduct Department at (213) 688-8090. You may also submit a written request to the following: Business Conduct Department, 1000 Wilshire Blvd., Los Angeles, CA 90017.

#### **OTHER DISCLOSURES**

# RESEARCH DEPT. \* (213) 688-4505 \* www.wedbush.com

EQUITY TRADING Los Angeles (213) 688-4470 / (800) 421-0178 \* EQUITY SALES Los Angeles (800) 444-8076 CORPORATE HEADQUARTERS (213) 688-8000

The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis; neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request.



### **EQUITY RESEARCH DEPARTMENT**

(213) 688-4529

#### DIRECTOR OF RESEARCH

Mark D. Benson (213) 688-4435

#### MANAGER, RESEARCH OPERATIONS

Ellen Kang (213) 688-4529

DETAI	IVND	CONS	SUMER
VE I VI	LAND	CON	

**Consumer Products** 

Rommel T. Dionisio (212) 938-9934 Kurt M. Frederick, CFA CPA (415) 274-6822 Alicia Reese (212) 938-9927

Footwear, Apparel and Accessories

Corinna Freedman (212) 668-9876

**Healthy Lifestyles** 

Kurt M. Frederick, CFA CPA (415) 274-6822 Alicia Reese (212) 938-9927

Restaurants

Nick Setyan (213) 688-4519 Colin Radke (213) 688-6624

Specialty Retail: Hardlines

Joan L. Storms, CFA (213) 688-4537 John Garrett, CFA (213) 688-4523

Seth Basham, CFA (212) 938-9954

Specialty Retail: Softlines

Morry Brown (213) 688-4311

RETAIL/CONSUMER MARKET RESEARCH

Gabriella Santaniello (213) 688-4557

## INDUSTRIAL GROWTH TECHNOLOGY

Clean Technology

Craig Irwin (212) 938-9926 Min Xu (212) 938-9925

**Environmental Services / Building Products** 

Al Kaschalk (213) 688-4539 Taryn Kuida (213) 688-4505

Water and Renewable Energy Solutions

David Rose, CFA (213) 688-4319 James Kim (213) 688-4380 TECHNOLOGY, INTERNET, MEDIA & SOCIAL MEDIA

**Communications and Application Software** 

Shyam Patil, CFA (213) 688-8062 Andy Cheng (213) 688-4548

Enterprise Security

Sanjit Singh (212) 938-9922

Ryan Flanagan (212) 938-9942

**Computer Services: Financial Technology**Gil B. Luria (213) 688-4501

Aaron Turner (213) 688-4429

**Enterprise Software** 

Steve Koenig (415) 274-6801 Kevin Ikeda (213) 688-4423

Entertainment: Retail

Michael Pachter (213) 688-4474 Nick McKay (213) 688-4343

Nick Citrin (213) 688-4495

**Entertainment: Software** 

Michael Pachter (213) 688-4474
Nick McKay (213) 688-4343
Nick Citrin (213) 688-4495

Internet: Media and Gaming

Michael Pachter (213) 688-4474
Nick McKay (213) 688-4343
Nick Citrin (213) 688-4495

Internet: Social Media, Advertising & Technology

Shyam Patil, CFA (213) 688-8062 Andy Cheng (213) 688-4548

Media

James Dix, CFA (213) 688-4315

**Movies and Entertainment** 

Michael Pachter (213) 688-4474
Nick McKay (213) 688-4343
Nick Citrin (213) 688-4495

Semiconductors

Betsy Van Hees (415) 274-6869 Ryan Jue, CFA (415) 263-6669 LIFE SCIENCES AND HEALTH CARE

Biotechnology/Biopharmaceuticals/BioDefense

Gregory R. Wade, Ph.D. (415) 274-6863 David M. Nierengarten, Ph.D. (415) 274-6862 Christopher N. Marai, Ph.D. (415) 274-6861

Dilip Joseph (415) 273-7308

**Emerging Pharmaceuticals** 

Liana Moussatos, Ph.D. (415) 263-6626

**Healthcare Services - Managed Care** 

Sarah James (213) 688-4503

**Medical Devices** 

Tao Levy (212) 938-9948

**Medical Diagnostics and Life Sciences Tools** 

Zarak Khurshid (415) 274-6823

EQUITY SALES EQUITY TRADING

(213) 688-4470 / (800) 444-8076 (213) 688-4470 / (800) 421-0178 Los Angeles Los Angeles San Francisco (415) 274-6800 San Francisco (415) 274-6811 (212) 938-9931 New York New York (212) 344-2382 Boston (617) 832-3700 Boston (617) 832-3700

CORPORATE HEADQUARTERS

1000 Wilshire Blvd., Los Angeles, CA 90017-2465
Tel: (213) 688-8000 www.wedbush.com